Rybrevant's Efficacy in Lung Cancer Countered by Significant Toxicity

The EGFR MET bispecific agent Rybrevant (Amivantamab) shows clear activity in EGFR-mutated lung cancer, but its significant toxicity profile has led to clinician hesitation for its frontline use. Despite demonstrating a survival benefit in the frontline MARIPOSA trial, experts note that its adoption